Haifa, Israel

Ari Ayalon

USPTO Granted Patents = 2 


 

Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2008-2010

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Ari Ayalon: Innovator in Pharmaceutical Chemistry

Introduction

Ari Ayalon is a notable inventor based in Haifa, Israel. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of atorvastatin calcium, a compound known for its effectiveness in lowering serum cholesterol levels. With a total of 2 patents to his name, Ayalon continues to impact the pharmaceutical industry through his innovative work.

Latest Patents

Ari Ayalon's latest patents focus on the polymorphic form of atorvastatin calcium. The first patent details the new atorvastatin calcium Form V, which includes processes for preparing this new form. Additionally, it discusses pharmaceutical compositions and dosage forms that incorporate this innovative form of atorvastatin calcium. This invention is crucial for enhancing the efficacy and stability of atorvastatin in medical applications.

Career Highlights

Ayalon is currently associated with Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. His work at Teva has allowed him to collaborate with other experts in the field, further advancing research and development in pharmaceutical formulations.

Collaborations

Some of Ari Ayalon's notable coworkers include Michal Levinger and Sofia Roytblat. Their collaborative efforts contribute to the innovative environment at Teva, fostering advancements in pharmaceutical research.

Conclusion

Ari Ayalon's contributions to the field of pharmaceutical chemistry, particularly through his patents on atorvastatin calcium, highlight his role as an influential inventor. His work continues to pave the way for advancements in cholesterol-lowering medications.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…